2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
Jansen C, Choi Y, Evans S, Greenwald R, Behnke J, Hartman C, Kissick H, Harik L, Bilen M. Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. Frontiers In Oncology 2023, 13: 1271255. PMID: 37860195, PMCID: PMC10582703, DOI: 10.3389/fonc.2023.1271255.Peer-Reviewed Original ResearchClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaTyrosine kinase inhibitor-targeted therapyResponse to systemic therapyWell-tolerated treatment optionCD8+T cell infiltrationCombination of immunotherapyResponse to nivolumabImmunotherapy to patientsMinimal adverse effectsVEGF-TKIDisease recurrenceCombination therapyTherapeutic regimensTherapeutic responseConsensus guidelinesTreatment optionsOptimal treatmentTumor tissuesRare typePatientsTherapy
2021
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
Martini D, Jansen C, Harik L, Evans S, Olsen T, Master V, Kissick H, Bilen M. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers In Oncology 2021, 11: 793808. PMID: 34976834, PMCID: PMC8716393, DOI: 10.3389/fonc.2021.793808.Peer-Reviewed Original ResearchCD8+ T cellsResponse to treatmentT cellsLymphovascular invasionTranslocation-associated renal cell carcinomaFoci of lymphovascular invasionBiomarker of response to treatmentRadiographic response to treatmentFirst-line treatment optionFavorable response to treatmentIntratumoral immune infiltrationImmune checkpoint inhibitorsResponse to nivolumabRenal cell carcinomaPrimary tumor samplesYear old femalePresence of lymphocytesCheckpoint inhibitorsProgression-freeRare malignancyCell carcinomaPredictive biomarkersImmune infiltrationAggressive malignancyTreatment options